




RealRate

PHARMACEUTICAL 2017

Sonoma Pharmaceuticals Inc. Rank 145 of 292





RealRate

PHARMACEUTICAL 2017

Sonoma Pharmaceuticals Inc. Rank 145 of 292



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 124% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 80% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	12,888
Cost of Goods Sold	7,874
Intangible Assets	0
Liabilities, Current	3,551
Liabilities, Non-Current	0
Other Assets	65
Other Compr. Net Income	0
Other Expenses	23
Other Liabilities	112
Other Net Income	13
Other Revenues	15,084
Property and Equipment	850
Research and Development	1,806
Selling, General and Administrative Expense	15,556

Output Variable	Value in 1000 USD
Assets	13,803
Liabilities	3,663
Expenses	25,259
Revenues	15,084
Stockholders Equity	10,140
Net Income	-10,162
Comprehensive Net Income	-10,162
Economic Capital Ratio	83%